Global Commercializing Biomarkers Market Insights, Forecast to 2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 122

Report ID: 305421

The global Commercializing Biomarkers market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Commercializing Biomarkers market based on company, product type, end user and key regions.

This report studies the global market size of Commercializing Biomarkers in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Commercializing Biomarkers in these regions.
This research report categorizes the global Commercializing Biomarkers market by top players/brands, region, type and end user. This report also studies the global Commercializing Biomarkers market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI

Market size by Product
Consumables
Services
Software
Market size by End User
Oncology
Cardiology
Neurology
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Commercializing Biomarkers market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Commercializing Biomarkers market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Commercializing Biomarkers companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Commercializing Biomarkers submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Commercializing Biomarkers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Commercializing Biomarkers market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Commercializing Biomarkers Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Commercializing Biomarkers Market Size Growth Rate by Product
1.4.2 Consumables
1.4.3 Services
1.4.4 Software
1.5 Market by End User
1.5.1 Global Commercializing Biomarkers Market Size Growth Rate by End User
1.5.2 Oncology
1.5.3 Cardiology
1.5.4 Neurology
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Commercializing Biomarkers Market Size
2.1.1 Global Commercializing Biomarkers Revenue 2014-2025
2.1.2 Global Commercializing Biomarkers Sales 2014-2025
2.2 Commercializing Biomarkers Growth Rate by Regions
2.2.1 Global Commercializing Biomarkers Sales by Regions
2.2.2 Global Commercializing Biomarkers Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Commercializing Biomarkers Sales by Manufacturers
3.1.1 Commercializing Biomarkers Sales by Manufacturers
3.1.2 Commercializing Biomarkers Sales Market Share by Manufacturers
3.1.3 Global Commercializing Biomarkers Market Concentration Ratio (CR5 and HHI)
3.2 Commercializing Biomarkers Revenue by Manufacturers
3.2.1 Commercializing Biomarkers Revenue by Manufacturers (2014-2019)
3.2.2 Commercializing Biomarkers Revenue Share by Manufacturers (2014-2019)
3.3 Commercializing Biomarkers Price by Manufacturers
3.4 Commercializing Biomarkers Manufacturing Base Distribution, Product Types
3.4.1 Commercializing Biomarkers Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Commercializing Biomarkers Product Type
3.4.3 Date of International Manufacturers Enter into Commercializing Biomarkers Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Commercializing Biomarkers Sales by Product
4.2 Global Commercializing Biomarkers Revenue by Product
4.3 Commercializing Biomarkers Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Commercializing Biomarkers Breakdown Data by End User

6 North America
6.1 North America Commercializing Biomarkers by Countries
6.1.1 North America Commercializing Biomarkers Sales by Countries
6.1.2 North America Commercializing Biomarkers Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Commercializing Biomarkers by Product
6.3 North America Commercializing Biomarkers by End User

7 Europe
7.1 Europe Commercializing Biomarkers by Countries
7.1.1 Europe Commercializing Biomarkers Sales by Countries
7.1.2 Europe Commercializing Biomarkers Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Commercializing Biomarkers by Product
7.3 Europe Commercializing Biomarkers by End User

8 Asia Pacific
8.1 Asia Pacific Commercializing Biomarkers by Countries
8.1.1 Asia Pacific Commercializing Biomarkers Sales by Countries
8.1.2 Asia Pacific Commercializing Biomarkers Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Commercializing Biomarkers by Product
8.3 Asia Pacific Commercializing Biomarkers by End User

9 Central & South America
9.1 Central & South America Commercializing Biomarkers by Countries
9.1.1 Central & South America Commercializing Biomarkers Sales by Countries
9.1.2 Central & South America Commercializing Biomarkers Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Commercializing Biomarkers by Product
9.3 Central & South America Commercializing Biomarkers by End User

10 Middle East and Africa
10.1 Middle East and Africa Commercializing Biomarkers by Countries
10.1.1 Middle East and Africa Commercializing Biomarkers Sales by Countries
10.1.2 Middle East and Africa Commercializing Biomarkers Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Commercializing Biomarkers by Product
10.3 Middle East and Africa Commercializing Biomarkers by End User

11 Company Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Company Business Overview
11.1.3 Roche Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Roche Commercializing Biomarkers Products Offered
11.1.5 Roche Recent Development
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Details
11.2.2 Company Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Dako (Agilent Technologies) Commercializing Biomarkers Products Offered
11.2.5 Dako (Agilent Technologies) Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Company Business Overview
11.3.3 Merck Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Merck Commercializing Biomarkers Products Offered
11.3.5 Merck Recent Development
11.4 BD
11.4.1 BD Company Details
11.4.2 Company Business Overview
11.4.3 BD Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.4.4 BD Commercializing Biomarkers Products Offered
11.4.5 BD Recent Development
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Company Business Overview
11.5.3 Abbott Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Abbott Commercializing Biomarkers Products Offered
11.5.5 Abbott Recent Development
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details
11.6.2 Company Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers Products Offered
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Development
11.7 Affymetrix
11.7.1 Affymetrix Company Details
11.7.2 Company Business Overview
11.7.3 Affymetrix Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Affymetrix Commercializing Biomarkers Products Offered
11.7.5 Affymetrix Recent Development
11.8 Agendia
11.8.1 Agendia Company Details
11.8.2 Company Business Overview
11.8.3 Agendia Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Agendia Commercializing Biomarkers Products Offered
11.8.5 Agendia Recent Development
11.9 ALMAC
11.9.1 ALMAC Company Details
11.9.2 Company Business Overview
11.9.3 ALMAC Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.9.4 ALMAC Commercializing Biomarkers Products Offered
11.9.5 ALMAC Recent Development
11.10 Arrayit
11.10.1 Arrayit Company Details
11.10.2 Company Business Overview
11.10.3 Arrayit Commercializing Biomarkers Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Arrayit Commercializing Biomarkers Products Offered
11.10.5 Arrayit Recent Development
11.11 Biocartic
11.12 BG Medicine
11.13 KEGG EXPRESSION Database
11.14 Thermo Fisher
11.15 BGI

12 Future Forecast
12.1 Commercializing Biomarkers Market Forecast by Regions
12.1.1 Global Commercializing Biomarkers Sales Forecast by Regions 2019-2025
12.1.2 Global Commercializing Biomarkers Revenue Forecast by Regions 2019-2025
12.2 Commercializing Biomarkers Market Forecast by Product
12.2.1 Global Commercializing Biomarkers Sales Forecast by Product 2019-2025
12.2.2 Global Commercializing Biomarkers Revenue Forecast by Product 2019-2025
12.3 Commercializing Biomarkers Market Forecast by End User
12.4 North America Commercializing Biomarkers Forecast
12.5 Europe Commercializing Biomarkers Forecast
12.6 Asia Pacific Commercializing Biomarkers Forecast
12.7 Central & South America Commercializing Biomarkers Forecast
12.8 Middle East and Africa Commercializing Biomarkers Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Commercializing Biomarkers Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer